Détail de l'éditeur
Documents disponibles chez cet éditeur (463)
Rapport
OEDT = EMCDDA ; C. KROGER ; H. WINTER ; R. SHAW ; L. LEONE | Lisbon : OEDT / EMCDDA | Manuals | 2012The EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe. These guidelines[...]Rapport
FRANÇAIS : En octobre 1999 le CHADS (Edimbourg) et l'université d'Amsterdam ont été sollicités dans le cadre de la politique de l'OEDT de mise à disposition d'outils pour les professionnels de la réduction de la demande. Ce projet vise à facil[...]Rapport
ENGLISH : The main objective of the guidelines is to provide a European audience with basic information on the options, elements and procedures of drug-related treatment evaluation. The target readership includes professionals working in treat[...]Rapport
Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug use that cannot be reliably measured by surveys. T[...]Rapport
FRANÇAIS : En juin 1997, le Conseil de l'Union Européenne voulant suppléer aux différences de législation sur les nouvelles drogues de synthèse dans les Etats membres de l'Union Européenne, a adopté une action commune permettant l'échange d'in[...]Rapport
At least 1.1 million Europeans are estimated to have received treatment for drug dependence during 2009, mostly through opioid substitution, detoxification and psychosocial interventions, delivered in a variety of settings. While more than half [...]Rapport
OEDT = EMCDDA ; J. HILLEBRAND ; D. OLSZEWSKI ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2006FRANÇAIS : Cette étude thématique met en évidence un intérêt croissant des jeunes européens pour l'expérimentation des champignons hallucinogènes. Les enquêtes menées auprès d'élèves scolarisés (15-16 ans) montrent que la prévalence de l'usage[...]Rapport
ENGLISH : This Handbook is intended to be a reference toolbox for everyone planning, organising or executing a survey about drug use among the general population. The Handbook is, to a large extent, a compilation, summary and editing of the fi[...]Livre
T. RHODES ; D. HEDRICH, Éditeur scientifique | Lisbon : OEDT / EMCDDA | Monographs, ISSN 1606-1691 | 2010Part I of the monograph looks back at the emergence of harm reduction approaches and their diffusion, and explores the concept from different perspectives, including international organisations, academic researchers and drug users. Part II is de[...]Document multimédia
FRANÇAIS : L'OEDT vient d'ajouter sur son site une section présentant une vue d'ensemble des pratiques de réduction des méfaits pour 30 pays européens. Pour chacun des pays, on peut trouver : • une description du contexte national ; • une de[...]Document multimédia
The Health and social responses to drug problems: a European guide 2021 was developed to support practitioners and policymakers in tackling the negative consequences of drug use. The guide is composed of four sets of miniguides that look at resp[...]Rapport
FRANÇAIS : Comment répondre aux problèmes des héroïnomanes âgés ? Comment lutter contre les décès causés par le fentanyl et ses dérivés extrêmement puissants ? Comment prévenir les risques dus à la consommation d'alcool et de drogues lors des f[...]Rapport
Performance- and image-enhancing drugs (PIEDs) include a wide range of drugs across various pharmacological categories and are subject to different legal controls and medicinal regulation across European countries. Their common feature is the fu[...]Rapport
OEDT = EMCDDA ; A. PIRONA ; A. ATKINSON ; H. SUMNALL | Lisbon : OEDT / EMCDDA | Rapid communication | 2016FRANÇAIS : Bien que l'usage de NPS en Europe demeure relativement faible, l'EMCDDA s'alarme des risques liés à la consommation de ces substances. Les données récentes mettent en évidence que les NPS sont à l'origine d'urgences hospitalières et [...]Rapport
This report provides an overview of principles of effective health risk communication for a drug checking service audience. The contents of this report are based on the findings of international evidence reviews of health risk communication, com[...]Rapport
OEDT = EMCDDA ; M. HICKMAN, Éditeur scientifique ; N. K. MARTIN, Éditeur scientifique ; I. GIRAUDON ; L. WIESSING ; D. HEDRICH ; E. KALAMARA ; P. GRIFFITHS ; R. SIMON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016FRANÇAIS : L'hépatite C est une maladie infectieuse du foie causée par le virus de l'hépatite C (VHC) qui peut être transmis par le sang. Environ 115 millions de personnes à travers le monde ont été infectées à un moment donné de leur vie par l[...]Livre
JAGER J. ; LIMBURG W. ; M. KRETZSCHMAR ; POSTMA M. ; L. WIESSING, Éditeur scientifique | Lisbon : OEDT / EMCDDA | Monographs, ISSN 1606-1691 | 2004ENGLISH : Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on he[...]Rapport
OEDT = EMCDDA ; I. UJVARY ; M. EVANS-BROWN ; A. GALLEGOS ; G. PLANCHUELO ; J. DE MORAIS ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Technical reports | 2023The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available. The European situation presented in Section 1 can only provide an overvie[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; M. RUIZ ; A. BO ; T. GROSHKOVA ; J. MATIAS ; L. VANDAM ; F. CARDOSO ; R. CHRISTIE ; L. MONTANARI ; I. GIRAUDON ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2017This report provides a first look at the emergence of more problematic forms of use of new psychoactive substances among a range of demographic groups, including opioid and amphetamine injectors, prisoners, the homeless and men who have sex with[...]Rapport
OEDT = EMCDDA ; European Centre for Disease Prevention and Control | Lisbon : OEDT / EMCDDA | Joint publications | 2012ENGLISH: In response to a notified increase in HIV cases among injecting drug users (IDU) in Greece and Romania, the European Commission asked the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for [...]Rapport
FRANÇAIS : Les données des services d'urgences hospitalières montrent que, chaque année, en Europe, des milliers de personnes subissent des empoisonnements et autres problèmes liés aux drogues qui nécessitent une forme d'assistance médicale. Da[...]Rapport
Contingency management (CM) is a general behavioural intervention technique used in the treatment of drug dependence to systematically arrange consequences and it is designed to weaken drug use and strengthen abstinence. The main elements of CM[...]Congrès
Rapport
OEDT = EMCDDA ; A. PIRONA ; L. MONTANARI ; I. GIRAUDON ; J. MATIAS ; K. OIEN ; L. VANDAM ; T. SURMONT ; B. GUARITA ; F. MATHIS ; J. MOUNTENEY ; K. NATONIEWSKA ; S. SLEIMAN ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2021Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and dru[...]Rapport
OEDT = EMCDDA ; J. FOUNTAIN ; G. BURKHART ; L. MONTANARI | Lisbon : OEDT / EMCDDA | Technical reports | 2017This report provides an overview of the various types of brief interventions (BIs) currently used in European countries in the field of substance use, particularly illicit drugs. Targeted at policymakers and practitioners alike, it covers more t[...]Rapport
This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those re[...]Rapport
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council c[...]Rapport
ENGLISH : This report presents the results of a European project to improve the comparability of general population surveys on drug use prevalence. The project was commissioned by the EMCDDA and carried out by O+S Amsterdam, in close cooperati[...]Rapport
OEDT = EMCDDA ; D. HEDRICH ; K. PALCZAK ; K. KEPA ; N. SINGLETON | Lisbon : OEDT / EMCDDA | Manuals | 2021This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]Rapport
T. RHODES ; M. BARNARD ; J. FOUNTAIN ; F. HARIGA ; N. R. AVILES ; J. VICENTE ; U. WEBER | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2001ENGLISH : This study explores the role of qualitative research in understanding the lived experience, social meanings and contexts of injecting drug use and risk behaviour in the time of AIDS, based on the findings of an EMCDDA working group i[...]Rapport
H. P. TOSSMANN ; LEUSCHENR F. ; R. SIMON ; J. HILLEBRAND ; A. PIRONA | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2009ENGLISH : This report provides a comprehensive review of the relatively new phenomenon of Internet-based drug treatment interventions (DTI). It presents a sample of Internet-based DTI programmes across Europe and outlines their methodologies, [...]Rapport
FRANÇAIS : Le présent projet avait pour objectif de rassembler l'information relative aux programmes de formation post-graduée sur les drogues existant en Europe, et d'étudier l'utilité et la faisabilité d'une mise en réseau de ces programmes [...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV ; A. ALMEIDA ; R. CHRISTIE ; P. DUQUE ; A. GALLEGOS ; R. JORGE ; J. DE MORAIS | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2020This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on [...]Rapport
The aim of this paper is to focus on the harmful interaction between psychoactive drug use and sexual activity. It is acknowledged that in some individuals co-occurrence of drug consumption and sexual activity causes no apparent harm, but this g[...]Rapport
This paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member States’ commitment to the issue. It also examines to what extent legal activity may be attributed to the EU action plan on drugs. Am[...]Rapport
This thematic paper looks at the extent to which legislative attention was paid in the period 2000-2004 to actions considered by Member States to be of high priority at the outset of the strategy and action plan. Over 250 legal texts were analys[...]Rapport
Osservatorio Epidemiologico Regione Lazio (Italie) | Lisbon : OEDT / EMCDDA | EMCDDA Literature reviews, ISSN 1725-0579 | 1997This is the final report of the EMCDDA project 'Review of scientific studies of mortality among drug users and feasibility study for a common methodology for monitoring overall and cause-specific mortality among drug users in Member States.' The[...]Rapport
FRANÇAIS : Cette synthèse de la littérature compare les différents modes de consommation de drogues, la conduite sous influence et les accidents de la route. Elle décrit également les procédures de dépistage des drogues, les législations exist[...]Brochure
In this brochure, the EMCDDA's Scientific Director takes us on a journey through 25 years of annual reporting on the drugs problem in Europe. The journey begins with the first report describing the drug situation in 1995 and leads us, over key m[...]Rapport
The open sale of cannabis products in Europe has raised concerns among policymakers, both with regard to the legal status of these products and their potential for harm. The products are marketed for their low THC (tetrahydrocannabinol) content,[...]Rapport
OEDT = EMCDDA ; M. P. SCHAUB ; J. Y. C. LEE ; A. PIRONA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals s[...]Rapport
L. ANNEMANS ; N. VANOVERBEKE ; J. TECCO ; F. HARIGA ; C. CARPENTIER ; R. HARTNOLL ; N. LALAM ; S. PARROTT | Lisbon : OEDT / EMCDDA | Scientific Reports | 2000ENGLISH : This is the final report of a study to develop a macro-economic model, simulating the career of potential heroin users and the accompanying demand for heroin. Additionally, the effects of different measures and changes in the setting[...]Rapport
This paper aims to provide an overview on the development of the evaluation process of the EU Strategy and Action Plan on Drugs. A large part of the initiatives and action impacting on the drug phenomenon are under the direct responsibility of [...]Rapport
K. KHAN ; K. ZERVOULLIS ; C. CARPENTIER ; R. HARTNOLL | Lisbon : OEDT / EMCDDA | Scientific Reports | 2000ENGLISH : It is sometimes assumed that minority/migrant populations are more likely to have problems with drug use than the "native populations". However they are also more likely to have other general problems, such as social and economic dis[...]Rapport
This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en-PINACA. The report is intended for policymakers and decision-makers in the inst[...]Rapport
OEDT = EMCDDA ; A. M. DINES ; D. M. WOOD ; P. I. DARGAN | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2014This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over t[...]Rapport
ENGLISH: What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other q[...]Congrès
Reitox Academy for Baltic countries: Monitoring trends in and responses to drug-related infectious diseases among people who inject drugs (21-22 November 2013; Tallinn) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This meeting, a regional Reitox Academy held in Tallinn (21-22 November 2013) contributed to maximising synergies at national level between institutions and experts in the fields of drug monitoring and infectious disease surveillance in four cou[...]Congrès
3rd Meeting on detecting and responding to outbreaks of HIV among people who inject drugs (18 November 2013; Bucharest) ; Roundtable on the HIV situation among people who inject drugs in Romania (19 November 2013; Bucharest) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This expert meeting held in Bucharest (18-19 November 2013) provided an important opportunity for sharing knowledge and best practice among experts from six countries in the south and south-east of the European region (Cyprus, Greece, Hungary, M[...]Rapport
This publication is the first in a series dedicated to prevalent illicit synthetic stimulant drugs, also known as amphetamine-type stimulants (ATS). The ATS category is made up of two groups of substances. This study focuses on the supply and us[...]